Drugs / SCT510
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT05113511 | May → Nov 2018 | — | First Affiliated Hospital of Zhejiang University | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04560894 | Nov 2020 → Apr 2024 | hepatocellular carcinoma | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03792074 | Feb 2019 → May 2021 | non-small cell lung carcinoma | Sinocelltech Ltd. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT510 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03792074 ↗ |
| Modality | Monoclonal antibody | “SCT510 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF)” PMID 37247166 ↗ May 2023 |
| Route | Intravenous | “Participants receive SCT510 intravenously，15mg/kg，d1，Q3w” NCT04560894 ↗ |